Meeting | Topics: 1)Medtronic Leading The Way In DBS – Speaker: Michelle Morton Reed 2)Demonstration – Parkinson’s & Movement Disorders Exercise Class – Presenters: Jessica Bacon, Annette Francis, Nancy Maxfield
MEDTRONIC - LEADING THE WAY IN DBS For the one million people diagnosed with Parkinson's disease in the United States, Medtronic, a global leader in healthcare technology, proudly announces FDA approval of BrainSense™ Adaptive deep brain stimulation (aDBS) and BrainSense™ Electrode Identifier (EI). Deep brain stimulation (DBS) has been transforming the lives of people with Parkinson's and other neurological disorders for more than 30 years. DBS is similar to a cardiac pacemaker, but for the brain. It uses a surgically implanted neurostimulator via a minimally invasive procedure to transmit electrical signals to specific parts of the brain affected by debilitating neurological disorders. Now Medtronic has enhanced its Percept™ DBS neurostimulators with exclusive BrainSense™ Adaptive technology, introducing aDBS for people living with Parkinson's. This feature personalizes therapy based on a patient's brain activity in real time – both in clinical settings and in daily life2. It provides enhanced therapy personalization for symptom control that automatically adjusts, minimizing the need for patients to manually adjust stimulation. "Medtronic is the only company in the world to offer an adaptive DBS system that dynamically adjusts therapy in real time. This new era in Parkinson's care represents more than a decade of intentional innovation ushering in personalized neuromodulation at scale that responds to a patient's changing needs, equipping […]